Core Viewpoint - The successful listing of Suzhou Aide Technology Development Co., Ltd. on the Beijing Stock Exchange marks a significant milestone, providing new capital support for its future development and enhancing its market confidence in the orthopedic medical device sector [1][3][10]. Listing Overview - Aide Technology raised approximately 227 million yuan through its transfer to the Beijing Stock Exchange, with plans to invest in orthopedic consumables expansion, R&D center construction, and marketing network expansion [3]. - The company issued about 29.53 million shares at a price of 7.67 yuan per share, achieving a first-day opening increase of over 220%, closing at 21.23 yuan per share, a rise of 176.79%, with a trading volume of 553 million yuan and a turnover rate of 89.61% [3]. - The successful listing not only provides capital support for further development but also strengthens the company's market position and potential for business expansion [3]. Performance Overview - In 2025, Aide Technology reported a revenue of 302 million yuan, a year-on-year increase of 9.74%, and a net profit of 77.75 million yuan, up 15.82% year-on-year [4]. - The company's operating profitability is strong, with a non-recurring net profit growth of approximately 17.99%, indicating high profit quality [4]. - Despite facing market challenges in 2023, the company adjusted its strategy and enhanced product R&D, achieving steady recovery in 2024 and 2025, with a revenue and net profit growth of about 19.07% in the first half of 2025 [4]. Product Layout - Aide Technology has focused on the research, production, and sales of orthopedic medical devices since its establishment, achieving significant success in spinal minimally invasive intervention and trauma repair [5][7]. - The company has a strong technical advantage in the spinal minimally invasive intervention field, with its vertebroplasty system ranking among the top three in the domestic market [7]. - Aide Technology is expanding its product layout into trauma repair and sports medicine, continuously investing in R&D to enrich its product line and aiming to become a comprehensive solution provider in the orthopedic medical device sector [7]. Development History - Since its establishment in 2006, Aide Technology has undergone multiple technological innovations and market breakthroughs, evolving from a small-scale enterprise focused on imitating imported products to a leading company in the domestic orthopedic medical device industry [8][9]. - The company's development history reflects its deep accumulation in the orthopedic medical device field and its adaptability to changing market conditions [9]. Conclusion - The successful transfer to the Beijing Stock Exchange provides Aide Technology with broader capital market resources and injects new vitality into its future development [10]. - With ongoing capital support, the company is expected to enhance its brand influence and pursue higher-level development, anticipating broader growth opportunities in domestic and international markets as it expands its product line and improves its technology [10].

Investment Rating - The report assigns a rating of "Buy" for the company, indicating an expected price increase of over 15% compared to the benchmark index within 6-12 months [58]. Core Insights - The company, Aide Technology, is a leading domestic player in the spinal vertebral body shaping system, benefiting from the aging population and increasing demand for orthopedic medical devices [3][28]. - The orthopedic implant medical device industry is projected to reach a market size of 24.6 billion yuan in 2024, driven by the aging population and increasing treatment penetration rates [4][36]. - The company has established a comprehensive product matrix covering 132 products across various orthopedic fields, including spinal, trauma, and sports medicine [5][35]. Summary by Sections Market Data - Total share capital is 0.89 billion shares [1]. Financial Data - The company is expected to achieve revenues of 2.86 billion yuan, 2.62 billion yuan, 2.75 billion yuan, and 3.02 billion yuan from 2022 to 2025, with year-on-year growth rates of -4.11%, -8.22%, 4.87%, and 9.74% respectively [6][47]. - Net profit for the same period is projected to be 9327.94 million yuan, 6356.86 million yuan, 6713.05 million yuan, and 7775.27 million yuan, with growth rates of -0.21%, -31.85%, 5.60%, and 15.82% respectively [6][47]. Company Overview - Aide Technology focuses on the research, production, and sales of orthopedic consumables, including spinal, trauma, and sports medicine products [3][28]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including "Jiangsu Province Specialized and Innovative Small and Medium Enterprises" [3][28]. Competitive Advantages - The company has a well-established national sales network and a deep communication mechanism with hospitals and orthopedic doctors, enhancing product recognition and market penetration [5][35]. - Aide Technology has obtained 108 patents, with a research and development investment ratio of 6.96% from 2022 to 2024, indicating a strong commitment to innovation [5][35]. Market Trends - The demand for orthopedic implants is driven by a high prevalence of osteoporosis and vertebral compression fractures among the elderly population, with over 32% of individuals aged 65 and above affected [4][36]. - The company is adapting to the normalized procurement policies by promoting non-procurement products, which have shown steady growth, partially offsetting the revenue decline from procurement products [47]. Valuation Analysis - The company's projected price-to-earnings (PE) ratio for 2024 is 13.50, which is at a discount compared to comparable companies in the industry, whose average PE is 57.78 [25][26].

Investment Rating - The report assigns a rating of "Buy" for the company, indicating an expected price increase exceeding 15% relative to the benchmark index within 6-12 months [58]. Core Insights - The company, Aide Technology, is a leading domestic player in the spinal vertebral body shaping system, benefiting from the aging population and increasing demand for orthopedic medical devices [3][28]. - The orthopedic implant medical device industry is projected to reach a market size of 24.6 billion yuan in 2024, driven by the aging population and increasing treatment penetration rates [4][36]. - The company has established a comprehensive product matrix covering 132 items across various orthopedic fields, including spinal, trauma, and sports medicine [5][35]. Summary by Sections Market Data - Total share capital is 0.89 billion shares [1]. Financial Data - The company is expected to achieve revenues of 2.86 billion yuan, 2.62 billion yuan, 2.75 billion yuan, and 3.02 billion yuan from 2022 to 2025, with year-on-year growth rates of -4.11%, -8.22%, 4.87%, and 9.74% respectively [6][47]. - Net profit for the same period is projected to be 93.28 million yuan, 63.57 million yuan, 67.13 million yuan, and 77.75 million yuan, with growth rates of -0.21%, -31.85%, 5.60%, and 15.82% respectively [6][47]. - The company's gross margin is expected to be 62.45%, 57.80%, 58.05%, and 58.90% from 2022 to 2025 [50]. Business Overview - Aide Technology focuses on the research, production, and sales of orthopedic consumables, including spinal, trauma, and sports medicine products [3][28]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including "Jiangsu Province Specialized and Innovative Small and Medium-sized Enterprises" [3][28]. Competitive Position - The company ranks third among domestic manufacturers of spinal vertebral body shaping systems and sixth among spinal implant manufacturers [3][28]. - Aide Technology has a well-established national sales network and a strong communication mechanism with hospitals and orthopedic surgeons, enhancing product recognition and market penetration [5][35]. Investment Analysis - The company is positioned to benefit from the ongoing trend of centralized procurement in the industry, which is expected to normalize pricing and enhance market opportunities [4][36]. - The company’s revenue from non-procurement products is growing, helping to offset declines in procurement product revenues [47]. Use of Proceeds - The company plans to use the proceeds from its public offering for expanding orthopedic consumables production, building a research center, and enhancing its marketing network [53][54].

Group 1: Company Overview - Yisiwei is a leading domestic company in automotive manufacturing machine vision equipment, holding the largest market share in China [2] - Aide Technology specializes in orthopedic consumables, focusing on the research, production, and sales of medical devices [3] Group 2: Financial Performance - Yisiwei's projected revenues for 2022 to 2024 are 223 million, 355 million, and 392 million yuan, with net profits of 6 million, 61 million, and 86 million yuan respectively [2] - Aide Technology's projected revenues from 2022 to 2025 are 286 million, 262 million, 275 million, and 302 million yuan, with net profits of 93 million, 64 million, 67 million, and 78 million yuan respectively [3] Group 3: Market Position and Growth Potential - Yisiwei's products are widely used by mainstream joint ventures, domestic new forces, and well-known automotive parts companies, indicating strong market penetration [2] - Aide Technology ranks third in the domestic market for spinal vertebroplasty systems and sixth for spinal implant medical devices, showcasing its competitive position [3] Group 4: Upcoming IPO Details - Yisiwei's IPO price is set at 55.95 yuan per share with a price-to-earnings ratio of 90.39, while Aide Technology's IPO price is 7.67 yuan per share with a price-to-earnings ratio of 14.98 [1][3]

Investment Rating - The report gives a positive investment rating for Aide Technology, highlighting its leadership in orthopedic consumables and the dual opportunities presented by aging population and domestic substitution [1]. Core Viewpoints - Aide Technology focuses on the research, production, and sales of orthopedic medical devices, covering spinal, trauma, joint, and sports medicine fields, with a projected 13.76% increase in net profit attributable to shareholders in 2025 [1][10]. - The company ranks third in the domestic market for spinal vertebroplasty systems and sixth for spinal implant medical devices, indicating a strong market position [1][11]. - The orthopedic medical device market in China is expected to grow from 193 billion yuan in 2016 to 246 billion yuan in 2024, with a compound annual growth rate (CAGR) of 3.08% [2][9]. Company Overview - Aide Technology is a national high-tech enterprise with various accolades, including recognition as a "specialized and innovative small and medium-sized enterprise" in Jiangsu Province [1][11]. - The company has developed a comprehensive product line that includes vertebroplasty systems, trauma implants, and wound healing products, with a focus on clinical needs [10][15]. - As of November 24, 2025, Aide Technology holds 110 patents, including 45 invention patents, and has established a strong technical advantage in its niche markets [11][12]. Financial Performance - For the first three quarters of 2025, the company reported revenues of 222.69 million yuan and a net profit of 59.55 million yuan, with forecasts for 2025 showing revenues of 307.48 million yuan and net profits of 76.37 million yuan [1][2]. - The company’s gross profit margins have shown slight fluctuations, with rates of 62.45%, 57.80%, 58.05%, and 58.89% from 2022 to the first half of 2025 [7][12]. Industry Insights - The report notes that the trend of centralized procurement in the orthopedic industry is stabilizing, reducing the likelihood of further significant price drops [2][9]. - The orthopedic implant market has seen a decline in 2022-2023 due to centralized procurement policies, but opportunities remain in non-procurement products and overseas markets [2][9]. - The aging population in China is expected to drive demand for orthopedic products, as the incidence of related diseases increases [2][9].

Investment Rating - The report does not explicitly state an investment rating for the company [1]. Core Insights - The company, Aide Technology, is a leading player in the orthopedic consumables sector, focusing on the full chain of orthopedic medical devices, including spinal, trauma, and sports medicine products, and is positioned to benefit from both aging population trends and domestic substitution opportunities [1][10]. - The company is expected to achieve a revenue of 307.48 million yuan and a net profit of 76.37 million yuan in 2025, representing year-on-year growth of 11.87% and 13.76% respectively [1]. - The orthopedic implant medical device market in China is projected to grow from 19.3 billion yuan in 2016 to 24.6 billion yuan in 2024, with a compound annual growth rate (CAGR) of 3.08% [2][9]. Company Overview - Aide Technology specializes in the research, production, and sales of orthopedic consumables, with a product range that includes spinal, trauma, sports medicine, and wound healing products [1][10]. - The company has been recognized as a national high-tech enterprise and has received various accolades, including being named a "Suzhou Brand Product" for its vertebroplasty system and external fixation bracket [1][11]. - As of November 24, 2025, the company holds 110 patents, including 45 invention patents, and has established a strong technical foundation in several core technologies [11]. Financial Performance - For the first three quarters of 2025, the company reported revenues of 222.69 million yuan and a net profit of 59.55 million yuan [1]. - The company’s gross profit margins for 2022 to the first half of 2025 were 62.45%, 57.80%, 58.05%, and 58.89% respectively [7][9]. - The company’s revenue structure is heavily reliant on manufacturing products, which accounted for 96.29% of total revenue in the first half of 2025 [41]. Industry Analysis - The orthopedic industry is experiencing a trend of price reductions due to centralized procurement policies, but the impact is expected to moderate, allowing for potential growth in non-procurement products and overseas markets [2]. - The market for vertebroplasty consumables in China grew from 800 million yuan in 2016 to 2.171 billion yuan in 2022, although it faced a decline in 2023 due to procurement policies [2][9]. - The aging population in China is expected to drive demand for orthopedic products, as the proportion of individuals aged 65 and older is steadily increasing [9].

Core Viewpoint - The listing of Aide Technology on the Beijing Stock Exchange represents both a culmination of efforts and a timely opportunity, occurring at a pivotal moment in the orthopedic consumables industry, which is undergoing a reshuffle due to normalized bulk purchasing practices [2]. Industry Background: "Re-distribution" After Bulk Purchasing - The past two years have seen comprehensive coverage of bulk purchasing in the spine, trauma, and joint segments, shifting hospital procurement logic from "price comparison" to "supply chain," "service," and "long-term stability" [3]. - Demand for orthopedic surgeries continues to grow due to factors like aging, osteoporosis, and the expansion of grassroots hospitals, maintaining the volume of consumables while reshaping the competitive landscape among companies [3]. - Discussions at this year's COA have shifted from mere "replacement" to efficiency, supply chain security, and the practical implementation of intelligent systems [3]. Company Profile: A Path Built on Fundamentals - Founded in 2006, Aide Technology specializes in four main product categories: spine, trauma, sports medicine, and wound repair, primarily focusing on consumables in the orthopedic sector [4]. - The company excels in two areas: the vertebroplasty system, where it holds a leading market position, and its channel system targeting lower-tier hospitals and non-top-tier public institutions [4]. Technical Reserves and Market Strategy - Aide Technology holds 110 patents, including 45 invention patents, and has 33 Class III certificates, with some core products certified by CE [6]. - Unlike leading companies that focus on major hospitals, Aide Technology targets the "basic market" of city-level and county hospitals, which presents both strong customer loyalty and significant challenges [6]. Capital Journey: A Bumpy Path Over Ten Years - The recent approval for listing is not Aide Technology's first attempt; the company has made three attempts over ten years, reflecting its evolving path in the capital market [7][8]. - The company has consistently focused on its orthopedic core business, with its path choices influenced by industry cycles, company size, and product structure [8]. Financial Performance: Volatility Reflecting Industry Logic - Aide Technology's financial performance shows volatility, with profits declining from a peak in 2022 and expected to stabilize in a tighter range from 2023 to 2025 [11]. - Key financial data includes total assets of approximately 652 million yuan as of June 30, 2025, and a net profit of about 38 million yuan for the same period [12]. - The primary revenue source is spinal products, which have been significantly impacted by bulk purchasing, leading to direct revenue pressure [13]. Inquiry Focus: Real Risks and Improvement Directions - During the listing review, regulators raised concerns about the ongoing impact of bulk purchasing, the standardization of the distribution system, and the robustness of management and internal controls [18]. - The company has faced issues such as frequent changes in distributors and high dependency on key personnel, necessitating a more standardized regional channel management system [19]. Fundraising Direction: Importance of Expansion, R&D, and Channels - The 197 million yuan raised will be allocated to three key areas: expansion, R&D, and channel development, all aimed at ensuring the company's long-term operational capability in the new industry environment [21]. - Expansion focuses on stabilizing production capabilities under price pressures, while R&D aims to address structural shortcomings in product development [22][23]. - Channel development seeks to enhance regional coverage, standardize training and delivery, and ensure transparency in the distribution system, all of which are crucial for future order stability [24]. Conclusion - Aide Technology's journey reflects the challenges and opportunities faced by mid-sized companies in the orthopedic industry, particularly in the context of bulk purchasing impacts and the need for standardization [25]. - The recent listing is not merely a celebration but a strategic move for the company to recalibrate itself within the industry during a period of structural upgrades [26].

Core Viewpoint - Aide Technology (Suzhou Aide Technology Development Co., Ltd.) is facing significant challenges on its path to IPO, including the impact of centralized procurement policies, financial internal control issues, and high ownership concentration by its actual controllers [1] Group 1: Financial Performance - The company's main products, spinal and trauma consumables, have been fully included in the national centralized procurement scope, leading to a sharp decline in sales revenue from 137 million yuan in 2022 to 84 million yuan in 2024, a decrease of 38.7% [1] - The prices of key products have experienced drastic reductions: the price of the vertebroplasty system dropped from 478.65 yuan in 2022 to 176.45 yuan in 2024, a decline of 63%; spinal implant products decreased from 193.08 yuan to 98.62 yuan, nearly a 50% drop; and bone cement prices fell from 475.74 yuan to 240.74 yuan, also nearly a 50% decrease [1] - In 2024, the company reported a revenue of 275 million yuan, a year-on-year increase of 4.87%, and a net profit attributable to shareholders of 67.16 million yuan, up 5.60% year-on-year, primarily driven by increased sales volume despite significant price reductions impacting gross margins [1] Group 2: Sales and Distribution Model - The company's sales model heavily relies on distributors, with revenue from this model accounting for 97.71%, 94.07%, 87.08%, and 83.85% over the reporting periods, significantly higher than comparable companies in the industry [2] - There are discrepancies in sales data reported to different regulatory bodies, with significant differences in sales prices to the same distributor, raising concerns about the reliability of information disclosure [2] Group 3: Distributor Issues - A significant portion of revenue comes from distributors with questionable legitimacy, including those established after the start of their cooperation and those with very low or zero registered capital [3] - In 2022 and 2023, revenue from canceled distributors accounted for 14.87% and 6.42% of total revenue, respectively, raising doubts about the authenticity and accuracy of revenue recognition [3] Group 4: Ownership and Governance - The actual controllers, Lu Qiang and Huang Meiyu, hold a combined 79.07% of the company's shares, leading to concerns about potential risks associated with concentrated control and its impact on minority shareholders [3] - The company has a high dependency on key executive Li Yifei, who has been responsible for sales and channel management, and there are regulatory concerns regarding the zero-cost transfer of shares to him, which raises questions about corporate governance [4]